European Union · Phase III and Phase II/III · HNSCC
EU Phase III HNSCC trials: sites, PIs and country recruitment plans
Gustave Roussy leads the late-stage HNSCC site network with 16 trial participations across 29 Phase III-containing studies. Tomasz Rutkowski leads investigator experience with 13 trial participations, while France carries the broadest country footprint among the leading recruitment markets.
Top 10 sites · All HNSCC populations
Gustave Roussy leads with 16 trial participations
Institut Català d'Oncologia follows with 13. Six other centres contributed to 12 trials each.
Targeted populations
OropharyngealFour explicitly defined studiesCentre Antoine Lacassagne, Hôpital Tenon and Gustave Roussy each contributed to three.
Previously treated R/MFour systemic-treatment studiesCentre Léon Bérard, Fondazione IRCCS Istituto Nazionale dei Tumori, Narodowy Instytut Onkologii, Leipzig and Pécs each contributed to three.
Trial participation reflects documented HNSCC experience, not current recruitment capacity or site performance.
Top 10 principal investigators · All HNSCC populations
Tomasz Rutkowski leads investigator experience with 13 trials
Francesco Perri has contributed to nine trials. Bohuslav Melichar, Lisa Licitra, Paolo Bossi and Willem Lybaert each contributed to eight.
Targeted populations
OropharyngealFour explicitly defined studiesFlorence Huguet contributed to three, followed by Xu-Shan Sun with two.
Previously treated R/MFour systemic-treatment studiesAndreas Dietz, Szabolcs Bellyei and Tomasz Rutkowski each contributed to three.
Country recruitment plans · All HNSCC populations
France combines the broadest trial footprint with the largest median country plan
France leads across 20 trials with a median planned allocation of 64 participants. Italy follows at 37 and Spain at 36 among the most frequently selected markets.
Targeted populations
OropharyngealFour explicitly defined studiesFrance leads the subgroup across three studies, with a median planned allocation of 400 participants.
Previously treated R/MFour systemic-treatment studiesGermany is included in all four. France, Italy and Spain each contribute to three, with median plans of 42, 40 and 40 participants.
Country figures are planned recruitment allocations, not completed enrollment. Country allocations can exceed the final global sample size when summed.
Operational CRO experience · All HNSCC populations
IQVIA leads documented CRO support across three programs
Medpace and Syneos Health each support two programs. Biorasi, Fortrea, PPD, SanaClis and Worldwide Clinical Trials each support one.
Targeted populations
OropharyngealFour explicitly defined studiesNo CRO supports more than one of the four studies.
Previously treated R/MFour systemic-treatment studiesMedpace, Syneos Health, Fortrea and Worldwide Clinical Trials each support one program.
CRO recurrence indicates documented HNSCC experience, not CRO quality or performance.
Source: CTIS trial records, country recruitment plans and trial documents, reviewed 19 September 2026. The cohort covers 29 anticancer Phase III and Phase II/III HNSCC studies with EU participation.